the hiv/aids diagnostic landscape: what does the future hold?

The HIV/AIDS Diagnostic Landscape: What does the Future Hold?

Maurine M. MurtaghIAS 2011

Rome, ItalyJuly 18, 2011

Access to diagnostics for the HIV patient in resource-limited settings has improved through collaborative efforts

• Funding availability has meant most rapid progress in HIV/AIDS

Millions of patients identified and more than 6.6 million initiated on antiretroviral therapy

• Governments and partners have scaled up testing services

HIV TB Malaria0

1

2

3

4

5

6 5.7

1.4

2.8

Cumulative Global Fund Disbursements (USD Billions), Year end 2009

2005 2006 2007 2008 20090

2

4

6

8

10

12

14

16

Annual CD4 Test Volumes

Global ART

In Care (LMIC only)

But, there is more work to be done. We would like to:

SIMPLIFY TESTING

IMPROVE ITS EFFICIENCY

REDUCE ITS COST

INCREASE OVERALL ACCESS TODIAGNOSTICS

BUT,

NOT DIMINISH THE QUALITY OF PATIENT CARE

Diagnostics for HIV/AIDS is a Continuum of Testing

ILLUSTRATIVE

N

eed

for S

ervi

ce

RapidTesting

and EID

CD4Resistance

Testing

Chemistry & Hematology

CD4 and

Viral Load

Chemistry & Hematology

Staging and Monitoring

Safety Tests for ART

InitiationMonitoring

1st LineMonitoring

2nd LineDiagnosis

Challenges at any one point can become bottlenecks for patients proceeding further through the HIV care and treatment program.

These blockages prevent full realization of potential volumes for ARVs and other tests further downstream, which impacts program costs and also reduces the number of patients proceeding healthily into and through the ART program.

The Current HIV Diagnostic Market

*1 test every 6 months for the ~6.6 million on ART + 6.6 million on care (CD4) or ~6.6 million on treatment (VL)

Factors Limiting Diagnostic Access

Diagnostic delivery of EID, CD4 and viral load testing is generally via large and relatively expensive laboratory-based systems that require well-trained technicians and good sample transport networks to provide access to testing for those in some urban, and virtually all peri-urban and rural settings.

• Even for patients who do have reliable access to testing, they often make multiple visits to health facilities to obtain a single test result, with the loss of travel costs and man-hours.

• In some rural settings, up to 40% of patients who receive a positive HIV diagnosis do not receive the follow-up tests they need to help them initiate treatment and monitor disease progression.

• Additionally, limited capacity at central labs often leads to long patient backlogs and waiting periods between tests.

And, further . . .

Solutions are Needed

New Diagnostic Technologies

The diagnostic landscape is beginning tochange and may change dramatically with the introduction of diagnostics designed to be delivered at or near the patient point of care (POC).

For the first time, we will have the opportunity to deliver EID, CD4 and viral load testing on site in peri-urban and rural settings.

The Promise of POC Testing

POC testing has the promise to:

• Reduce the need for large infrastructure investments in diagnostic equipment

• Reduce/eliminate the need for service and maintenance

• Reduce the per test cost of testing

• Yield same day results for prompt clinical decision-making

• Improve patient retention

• Reduce the need for sample transport network

The POC Diagnostic Pipeline

CD4 is the farthest along:

• Currently 3 POC or near POC devices on the market

• Several more to come, at least one of which will be disposable

Viral Load and EID:

• No POC devices currently on the market

• At least one on pace to launch in late 2011, early 2012

• More expected to follow in 2013

EID Only:At least 2 dedicated POC technologies for EID expected by 2013

CD4 Product Pipeline*

2009 2010 2011 2012 2013

PointCare

Partec Mini

PIMA

DaktariBurnet

mBio

Zyomyx

Instruments Disposable

*Estimated - timeline and sequence may change

BD

Technology Pipeline – Viral Load and EID*

2011 2012 2013 2014 2015

Alere

NWGHF VL

NWGHF EID

SAMBA EID SAMBA VL

LiatWAVE 80

EOSCAPE

Gene XPert

Micronics

Biohelix

ALL

The Limitations of POC Testing

POC testing has the promise to fill gaps in access and capacity, and there are some exciting POC diagnostics either here or coming over the next few years. But, there is no silver bullet technology yet.

Understanding the realistic value and preparing for the implementation challenges is imperative to increase access to the right populations in the right way.

POC Testing:• Is generally low throughput testing and may not be cost-effective

in high- to medium-throughput settings• Does not eliminate the need to improve/strengthen lab systems,

including HR/Training, Supply Chain, Service Delivery Design and Quality Assurance

If the goal for diagnostics going forward is robust, high-quality, efficient, cost-effective and accessible diagnostic services for the full complement of testing required to diagnose, stage and monitor the HIV patient effectively, this will require continued use of both centralized and POC testing for the foreseeable future.

Implications for UNITAID Funding

For countries where high throughput testing is required to provide improved access, there will likely be an increasing concentration of centralized testing facilities, including super labs. But, there are also opportunities to improve access and to lower the cost of CD4, viral load and EID with the strategic introduction of POC and near POC devices and tests.

Acknowledgments

UNITAID

Dr. Trevor Francis Peter

Advanced Liquid Logic, Alere, BD Biosciences, Biohelix Burnet, Cepheid, Daktari Diagnostics, Diagnostics for the Real World, Iquum, Micronics, Northwestern Global Health Foundation, Partec, PointCare, WAVE80, and Zyomyx

Thank you

Extra Slides

The Current Market for CD4, Viral Load and EID

• Except for rapid testing, each of the HIV test markets is dominated by a few suppliers of laboratory-based platforms:• CD4: BD, Coulter• Viral Load: Roche, Abbott, Siemens, bioMérieux• EID: Roche, Abbott

• Hard to quantify market due to incomplete reporting, but in 2010 approximate market was:• CD4 - ~14 million tests• Viral Load - ~2.5 million tests (dominated by RSA

and Brazil)• EID - ~600,000 tests

• Based on projected number of patients in care and on treatment, the market for each test category is expected to grow over the next 5 years.